- Oncology focused drug development firm Kazia Therapeutics has commenced Phase 2 clinical trial of its investigational new drug, paxalisib.
- CLINUVEL has enrolled the first acute arterial ischaemic stroke (AIS) patient for the treatment with afamelanotide in the CUV801 trial.
Two ASX healthcare shares, Kazia Therapeutics Limited (ASX:KZA, NASDAQ:KZIA) and CLINUVEL Pharmaceuticals Ltd (ASX:CUV), updated the market with announcements related to patient enrolment in their clinical studies.
Oncology player Kazia Therapeutics enrolled the first patient in paxilisib study. CLINUVEL updated that its drug afamelanotide was administered to the first patient suffering from an acute arterial ischaemic stroke (AIS).
On 7 June 2021, ASX 200 closed lower, down 0.19%. However, some healthcare shares ended the day on a positive note, including Medlab Clinical Limited (ASX:MDC), Oneview Healthcare PLC (ASX:ONE), ECS Botanics Holdings Ltd (ASX:ECS) and Medibio Limited (ASX:MEB).
Let us now discuss the updates of Kazia Therapeutics and CLINUVEL in detail-
First patient enrolled in Kazia’s paxilisib study
Oncology-focused drug development firm Kazia Therapeutics updated the market that the Phase 2 clinical trial of its investigational new drug, paxalisib, had been initiated. In addition, the Company stated that the first patient had been enrolled for the study.
Kazia revealed that this study was being performed at Dana-Farber Cancer Institute (DFCI) for the treatment of primary CNS lymphoma (PCNSL). DFCI is a Massachusetts-based world-leading cancer treatment and research centre.
Copyright © 2021 Kalkine Media
Lymphoma is a cancer of white blood cells and occurs in the lymphatic system. Besides, primary CNS lymphoma (PCNSL) occurs exclusively in the brain and CNS (central nervous system). Paxalisib belongs to the PI3K inhibitor class of drug that is well-validated in lymphoma outside the brain.
The study conducted at DFCI is an open-label Phase 2 clinical trial of paxalisib for the treatment of PCNSL and is expected to recruit up to 25 patients. The study is projected to complete in two years.
Furthermore, the Company will offer support, including study drug and a financial grant.
Dr James Garner, CEO of Kazia, commented-
On 7 June 2021, KZA shares last traded at AU$1.250, down by 1.575%.
CLINUVEL enrolled the first patient in Phase 2 CUV801 study
CLINUVEL revealed that its drug afamelanotide had been administered to the first patient suffering from an acute arterial ischaemic stroke (AIS) enrolled in the CUV801 trial.
CLINUVEL disclosed that, in total, six adult AIS patients would be evaluated in the Phase 2 CUV801 clinical trial. The study aims to evaluate the safety and therapeutic potential of afamelanotide in patients who are not qualified for standard stroke therapy.
Source: © Nastyazhi | Megapixl.com
The Company disclosed that the CUV801 study assesses the use of afamelanotide in six patients who have experienced an acute stroke. The main focus of the study will be monitoring safety following drug administration as the patients are admitted to the hospital.
Dr Pilar Bilbao, CLINUVEL Clinical Operations Manager, said-
On 7 June 2021, CUV shares closed at AU$27.95, down by 2.851%.